

# Yerong Yu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7230192/publications.pdf>

Version: 2024-02-01

38  
papers

731  
citations

687363

13  
h-index

552781

26  
g-index

42  
all docs

42  
docs citations

42  
times ranked

1265  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 17-26.	11.4	116
2	Free fatty acids, not triglycerides, are associated with non-alcoholic liver injury progression in high fat diet induced obese rats. <i>Lipids in Health and Disease</i> , 2016, 15, 27.	3.0	103
3	Free fatty acids induce endothelial dysfunction and activate protein kinase C and nuclear factor- $\kappa$ B pathway in rat aorta. <i>International Journal of Cardiology</i> , 2011, 152, 218-224.	1.7	70
4	Insulin resistance and endothelial dysfunction in type 2 diabetes patients with or without microalbuminuria. <i>Diabetes Research and Clinical Practice</i> , 2004, 65, 95-104.	2.8	46
5	High free fatty acids level related with cardiac dysfunction in obese rats. <i>Diabetes Research and Clinical Practice</i> , 2012, 95, 251-259.	2.8	37
6	Randomized Trial of Osilodrostat for the Treatment of Cushing Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2882-e2895.	3.6	31
7	Free fatty acid can induce cardiac dysfunction and alter insulin signaling pathways in the heart. <i>Lipids in Health and Disease</i> , 2018, 17, 185.	3.0	29
8	Down-regulation of myocardial infarction associated transcript 1 improves myocardial ischemia-reperfusion injury in aged diabetic rats by inhibition of activation of NF- $\kappa$ B signaling pathway. <i>Chemo-Biological Interactions</i> , 2019, 300, 111-122.	4.0	29
9	High FFA levels related to microalbuminuria and uncoupling of VEGF-NO axis in obese rats. <i>International Urology and Nephrology</i> , 2013, 45, 1197-1207.	1.4	27
10	Evaluation of the Saline Infusion Test and the Captopril Challenge Test in Chinese Patients With Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 853-860.	3.6	27
11	Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study. <i>Pituitary</i> , 2021, 24, 887-903.	2.9	21
12	Time-action Profile of an Oral Enteric Insulin Formulation in Healthy Chinese Volunteers. <i>Clinical Therapeutics</i> , 2012, 34, 2333-2338.	2.5	20
13	H1N1 Influenza: The Trigger of Diabetic Ketoacidosis in a Young Woman With Ketosis-Prone Diabetes. <i>American Journal of the Medical Sciences</i> , 2012, 343, 180-183.	1.1	16
14	Detrimental effects of hypercortisolism on brain structure and related risk factors. <i>Scientific Reports</i> , 2020, 10, 12708.	3.3	15
15	Sodium Infusion Test for Diagnosis of Primary Aldosteronism in Chinese Population. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 89-95.	3.6	13
16	A novel uromodulin mutation in autosomal dominant tubulointerstitial kidney disease: a pedigree-based study and literature review. <i>Renal Failure</i> , 2018, 40, 146-151.	2.1	12
17	Predictors of Long-Term Glycemic Remission After 2-Week Intensive Insulin Treatment in Newly Diagnosed Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2153-2162.	3.6	11
18	ACTH-independent Cushing's syndrome with bilateral cortisol-secreting adrenal adenomas: a case report and review of literatures. <i>BMC Endocrine Disorders</i> , 2018, 18, 22.	2.2	10

#	ARTICLE	IF	CITATIONS
19	Hypercortisolism and primary aldosteronism caused by bilateral adrenocortical adenomas: a case report. <i>BMC Endocrine Disorders</i> , 2019, 19, 63.	2.2	10
20	Protective effect of treatment with low-dose gliclazide in a model of middle cerebral artery occlusion and reperfusion in rats. <i>Brain Research</i> , 2014, 1560, 83-90.	2.2	9
21	Novel fatty chain-modified GLP-1R G-protein biased agonist exerts prolonged anti-diabetic effects through targeting receptor binding sites. <i>RSC Advances</i> , 2020, 10, 8044-8053.	3.6	9
22	Mineralocorticoid receptor excessive activation involved in glucocorticoid-related brain injury. <i>Biomedicine and Pharmacotherapy</i> , 2020, 122, 109695.	5.6	8
23	The prevalence of impaired glucose regulation in psychiatric patients with sleep disorders and its relationship with altered hypothalamopituitary-adrenal and hypothalamopituitary-thyroid axis activity. <i>Sleep Medicine</i> , 2013, 14, 662-667.	1.6	7
24	Unusual ectopic ACTH syndrome in a patient with orbital neuroendocrine tumor, resulted false-positive outcome of BIPSS:a case report. <i>BMC Endocrine Disorders</i> , 2020, 20, 116.	2.2	7
25	The usefulness of the combined high-dose dexamethasone suppression test and desmopressin stimulation test in establishing the source of ACTH secretion in ACTH-dependent Cushing's syndrome. <i>Endocrine Journal</i> , 2021, 68, 839-848.	1.6	7
26	Lower prevalence of proliferative diabetic retinopathy in elderly onset patients with diabetes. <i>Diabetes Research and Clinical Practice</i> , 2017, 125, 47-52.	2.8	6
27	Elevated thyroid-stimulating hormone levels are associated with poor sleep: a cross-sectional and longitudinal study. <i>Endocrine</i> , 2022, 75, 194-201.	2.3	6
28	Interindividual Variability in the Pharmacodynamic and Pharmacokinetic Characteristics of Recombinant Human Insulin and Insulin Aspart. <i>Clinical Therapeutics</i> , 2021, 43, 594-601.e1.	2.5	5
29	Computed tomography combined with confirmatory tests for the diagnosis of aldosterone-producing adenoma. <i>Endocrine Journal</i> , 2021, 68, 299-306.	1.6	4
30	Similar pharmacokinetics and pharmacodynamics of a new biosimilar and reference insulin aspart in healthy Chinese males. <i>Scientific Reports</i> , 2021, 11, 9495.	3.3	4
31	Acromegaly and non-parathyroid hormone-dependent hypercalcemia: a case report and literature review. <i>BMC Endocrine Disorders</i> , 2021, 21, 90.	2.2	4
32	A Euglycemic Glucose Clamp Study to Evaluate the Bioavailability of LY2963016 Relative to Insulin Glargine in Healthy Chinese Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 1452-1459.	1.6	4
33	Case Report: A Novel Point Mutation of SOX3 in a Subject With Growth Hormone Deficiency, Hypogonadotropic Hypogonadism, and Borderline Intellectual Disability. <i>Frontiers in Endocrinology</i> , 2022, 13, 810375.	3.5	3
34	Ketosis-prone diabetes mellitus in an obese adolescent. <i>Medicine (United States)</i> , 2019, 98, e16076.	1.0	2
35	Oscillations of C-peptide in the euglycemic clamp and their effect on the pharmacodynamic assessment of insulin preparations. <i>Fundamental and Clinical Pharmacology</i> , 2020, 35, 771-780.	1.9	1
36	MON-LB079 A Multicenter, Randomized, Open-Label, Phase IV Study Investigating Management of Pasireotide-Associated Hyperglycemia with Incretin-Based Therapy or Insulin in Patients with Acromegaly or Cushing's Disease (CD). <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	1

#	ARTICLE	IF	CITATIONS
37	Effects of Unsuppressed Endogenous Insulin on Pharmacokinetics and/or Pharmacodynamics of Study Insulin in the Healthy: A Retrospective Study. <i>Clinical Pharmacology in Drug Development</i> , 2022, 11, 930-937.	1.6	1
38	Commentary: Reduction in C-Peptide Levels and Influence on Pharmacokinetics and Pharmacodynamics of Insulin Preparations: How to Conduct a High-Quality Euglycemic Clamp Study. <i>Frontiers in Pharmacology</i> , 2022, 13, 843658.	3.5	0